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Abstract: Recent genetic studies have shown that PCSK9, one of the key genes in 
cholesterol metabolism, plays a critical role by controlling the level of low-density 
lipoprotein receptor. However, how PCSK9 mediates LDLR degradation is still unknown. 
By combining a shotgun proteomic method and differential analysis of natural occurring 
mutations of the PCSK9 gene, we found that an E3 ubiquitin ligase c-IAP1 binds and 
processes PCSK9 protein. One of the gain-of-function mutations, S127R, is defective 
with respect to binding to c-IAP1, and thus has defective autocatalytic activity. Knockdown 
of c-IAP1 impairs PCSK9 processing and autocatalytic cleavage. In c-IAP1 null mouse 
embryonic fibroblasts (MEFs), there is a dramatic decrease in secreted mature PCSK9 
protein accompanied by a significant increase in LDLR protein levels compared with 
matched wild-type MEF cells. c-IAP1 also acts as an E3 ligase for ubiquitination of 
PCSK9. Ubiquitin containing only lysine-27 mediated PCSK9 ubiquitination by c-IAP1. 
Given K27-linked polyubiquitination promotes lysosomal localization, the finding 
indicates the c-IAP1 acts on both secretion of PCSK9 and its lysosomal localization. The 
novel pathway described here will open new avenues for exploring novel disease treatments. 
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1. Introduction 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is encoded by one of three genes implicated 
in autosomal dominant hypercholesterolaemia (ADH), in addition to LDLR (low-density lipoprotein 
receptor) and APOB (apolipoprotein B). Recent genetic studies have shown that PCSK9 plays a 
critical role in cholesterol metabolism, by controlling the level of low-density lipoprotein receptor [1,2]. 
A wide spectrum of mutations in the PCSK9 gene has been found in the human population. PCSK9 
gain-of function variations are associated with hypercholesterolemia, whereas loss-of-function 
variations are associated with hypocholesterolemia [3,4]. 
PCSK9 belongs to a family of secretory serine proteinases known as proprotein convertases (PCs) [5]. 
It is synthesized as a 73 kDa zymogen and undergoes autocatalytic cleavage in the endoplasmic 
reticulum and it is secreted as a 63 kDa mature protein, which forms a complex with the N-terminal 
predomain [5]. To date, most studies of PCSK9 suggest it acts as a chaperone for LDLR and its related 
receptors, by directing them to the lysosomes for degradation. However, the precise mechanism by 
which PCSK9 escorts LDLR to lysosomes is still unknown. It has been suggested there are other 
interacting proteins, or co-receptors, which can associate with PCSK9 and LDLR to escort them into 
intracellular targets, such as endosomes, lysosomes or the cell surface [6,7]. 
In order to identify these proposed PCSK9 binding proteins, we have generated a FLAG-tagged 
PCSK9 expressing cell line and have used anti-FLAG antibody affinity purification and shotgun 
proteomic analysis to identify potential binding partners of PCSK9 and to study their roles in  
PCSK9-mediated LDLR degradation. 
2. Results and Discussion 
2.1. Identification of Potential PCSK9 Binding Proteins through Affinity Purification and Shotgun  
LC-MS/MS Analysis 
To identify novel binding partners of PCSK9, we generated a human T-Rex-293 stable cell line 
overexpressing FLAG-tagged wild-type PCSK9 [8] and PCSK9 carrying ADH mutations (p.S127R, 
D374Y, F216 L). The FLAG-tagged wild-type PCSK9 and associated proteins were isolated by 
performing anti-FLAG immunoprecipitation (IP) from cellular extracts; the eluted protein mixture was 
then subjected to shotgun proteomic analysis [9]. Briefly, protein complexes pulled down by 
immunoprecipitation with FLAG-tagged PCSK9 protein, were subjected to limited electrophoresis, 
after which 35 molecular weight regions were cut out and digested. Liquid chromatography/mass 
spectrometry/mass spectrometry (LC-MS/MS) was performed on each fraction. The lists of identified 
proteins for each sample (with their scores) were subjected to statistical validation and aligned for 
comparison using the Scaffold program. A negative control cell line, T-Rex-293 cells transfected with 
empty vector, pcDNA3.1, was used for background subtraction. 
In total, 22 co-IP proteins were identified (Table 1) that contain at least two unique spectra (two 
distinct peptides) in three independent experimental samples but were absent (zero spectra) in all three 
negative control samples. Many of these proteins are ER-localised proteins, such as the UDP-glucose 
glycoprotein glucosyltransferase 1 (UGGT-1), protein disulfide isomerase family A member 4 
(PDIA4, also called endoplasmic reticulum resident protein 72, ERP72) and calmegin (CLGN). Some 
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of the identified proteins are associated with the ubiquitination pathway, such as c-IAP1, TRAF2 and 
Stub1 E3 ligase. Others are molecular chaperones, such as DNJA1, DNJA2, DNJA3, DJB11, and 
DJC10 in the DnaJ (Hsp40) homolog subfamily. We also identified several mitochondrial carriers, 
including SLC25 A1, A10 and A12. 
Table 1. List of the potential PCSK9 binding proteins identified through affinity 
purification and shotgun LC-MS/MS analysis. Each protein was identified by at least two 
matched spectra (95% confidence minimum) in all three experiments (exp) with no 
spectrum identified in the control samples (empty vector, emp). 
Gene Symbols Gene Names 
Experiment 1 Experiment 2 Experiment 3 
emp exp emp exp emp exp 
PCSK9 proprotein convertase subtilisin/kexin type 9 3 1466 2 1171 4 1128 
UGGT1 UDP-glucose glycoprotein glucosyltransferase 1 0 9 0 12 0 15 
PDIA4 (ERP72) protein disulfide isomerase family A, member 4 0 7 0 5 0 7 
SLC25A1 solute carrier family 25 member 1  0 6 0 2 0 6 
DNAJA1 DnaJ (Hsp40) homolog, subfamily A, member 1 0 12 0 10 0 7 
CLGN Calmegin 0 2 0 2 0 2 
DNAJA2 DnaJ (Hsp40) homolog, subfamily A, member 2 0 2 0 3 0 4 
c-IAP1 (BIRC2) cellular inhibitor of apoptosis protein 1 0 7 0 9 0 8 
TBB6 tubulin, beta 6 0 5 0 2 0 3 
TRAF2 TNF receptor-associated factor 2 0 4 0 3 0 3 
SLC25A10 solute carrier family 25. member 10 0 6 0 3 0 6 
DNAJB11 DnaJ (Hsp40) homolog, subfamily B, member 11 0 5 0 4 0 3 
CDIPT 
CDP-diacylglycerol-inositol  
3-phosphatidyltransferase 0 3 0 6 0 4 
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 0 6 0 3 0 6 
DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 3 0 2 0 3 0 3 
RHOT1 ras homolog gene family, member T1 0 2 0 3 0 4 
AGK Acylglycerol kinase lipid kinase 0 2 0 3 0 2 
HSPB1 heat shock 27kDa protein 1 0 4 0 5 0 2 
RCN1 reticulocalbin 1 0 3 0 4 0 5 
Ribosomal L28 partial ribosomal protein L28 variant 0 2 0 6 0 5 
Stub1 STIP1 homology and U-box containing protein 1 0 2 0 3 0 2 
PGRC1 progesterone receptor membrane component 1 0 2 0 2 0 2 
SLC25A12 Solute carrier family 25 member 12 0 2 0 5 0 4 
2.2. c-IAP1/TRAF2 Complex Binds PCSK9 
We further confirmed five of the 22 PCSK9 binding proteins by Western blotting using commercial 
antibodies (Figure 1). Among the five proteins confirmed by Western blot (c-IAP1, TRAF2, UGGT-1, 
ERP72 and DNAJA-1), we observed that one of the gain-of-function mutants, PCSK9-S127R, 
which has impaired autocatalytic activity, was defective in binding to the c-IAP1 and TRAF2 proteins 
(Figure 1). c-IAP1 and TRAF2 are known binding partners in the TNF-Į-mediated apoptosis pathway [10]. 
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Figure 1. Immunoprecipitation (IP)/western blot analysis of novel PCSK9 binding proteins 
in the PCSK9-FLAG pull-down assay. Equal amount of cellular extracts from a T-Rex 293 
cell line stably overexpressing FLAG-tagged wild-type PCSK9 or  PCSK9 carrying ADH 
mutations (p.S127R, D374Y, F216 L) and a negative control cell line, T-Rex-293 cells 
transfected with the empty vector pcDNA3.1 (control) were subjected to anti-FLAG IP and 
Western blots probed with the antibodies indicated. 5% of the cell lysates prior to IP were 
used for the input, probed with anti-Į-tubulin antibody. The western blots shown are 
representative of three separate experiments.  
 
To further confirm the binding of c-IAP1 to wild-type PCSK9, we co-transfected wild-type  
FLAG-tagged PCSK9 (pCMV-PCSK9-FLAG) and myc-tagged cIAP-1 cloned into a pCMV6 
expression vector (Origene Inc., Rockville, MD, USA) into T-Rex-293 cells. The empty vector, 
pCMV6-entry vector (Origene, Inc.), was used as a control vector. After 24 h, the cell lysates were 
immunoprecipitated with anti-myc antibody. As shown in Figure 2A, the PCSK9 protein was detected 
in the IP pellet (Lane 2). To determine which regions of c-IAP1 were involved in binding to PCSK9, 
we made several deletion mutant constructs of c-IAP1 for PCSK9 binding studies. We found that only 
the region containing the baculoviral IAP repeat 3 (BIR3) domain of c-IAP1 could be used to pull 
down wild-type PCSK9 (Figure 2A, lane 3), indicating that c-IAP1-BIR3 is the binding site for 
PCSK9. The binding of PCSK9 to c-IAP1 was further confirmed using surface plasmon resonance 
(SPR) experiments, in which the binding affinities of the wild-type PCSK9 protein (isolated from the 
whole cell extract) for c-IAP1 were determined at pH 7.4 with a Kd of 44.3 ± 5 nM (n = 3, T100 
evaluation software, Supplementary Figure S1). We also used confocal microscopy to conduct 
immunostaining studies to confirm the colocalisation of PCSK9 and c-IAP1 in the cytoplasm of 293 
cells with stable overexpression of PCSK9 (Supplementary Figure S2). 
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Figure 2. c-IAP1 interacts with PCSK9. (A) Co-IP of PCSK9-wt and c-IAP1. Myc-tagged 
c-IAP1 or c-IAP1-BIR3 was co-transfected with either empty vector (pCMV6-entry 
vector) or FLAG-tagged wild-type PCSK9 into T-Rex-293 cells. Cell lysates were 
immunoprecipitated with an anti-myc tag antibody followed by immunoblotting with either 
anti-PCSK9 or anti-c-IAP1 antibodies; (B) Co-IP of PCSK9-wt, TRAF2 and LDLR.  
Myc-tagged TRAF2 or LDLR was co-transfected with FLAG-tagged wild-type PCSK9 
into T-Rex-293 cells. Cell lysates were immunoprecipitated with an anti-myc tag antibody 
followed by immunoblotting with either anti-PCSK9 or anti-TRAF or LDLR antibodies. 
The Western blots shown are representative of three separate experiments. 
 
We next determined whether TRAF2 binds to wild-type PCSK9. We co-transfected wild-type 
FLAG-tagged PCSK9 and myc-tagged TRAF2-pCMV6 expression vectors into T-Rex-293 cells.  
After 24 h, the cell lysates were immunoprecipitated with anti-myc antibody. We were unable to detect 
the PCSK9 protein in the IP pellet (Figure 2B, lane 2), indicating that TRAF2 was not a direct  
binding partner for PCSK9. c-IAP1 was thus the only physical binding partner of PCSK9 in the  
c-IAP1/TRAF2 complex. As a positive control, we co-transfected wild-type FLAG-tagged PCSK9 and 
Empty vector
c-IAP1-Myc - + -
c-IAP1-BIR3-Myc - - +
PCSK9 wild type + + +
PCSK9
IP: anti-Myc
WB
TRAF2
PCSK9 wild type + + +
IP: anti-Myc
LDLR-Myc - - +
WB
anti-PCSK9
anti-PCSK9
c-IAP1 anti-cIAP1
PCSK9
anti-TRAF2
78
78
kDa
210
78
kDa
78
55
55
55
55
210
+ - -
LDLR(M)
LDLR(P)
210
78
anti-LDLR
TRAF2-Myc - + -
input Tubulin
input Tubulin
A
B
Molecules 2012, 17 12091 
 
 
myc-tagged LDLR-pCMV6 into T-Rex-293 cells. After 24 h, the cell lysates were immunoprecipitated 
with an anti-myc antibody. We were able to detect the PCSK9 protein in the IP pellet (Figure 2B, lane 3), 
confirming LDLR binding to PCSK9 in our system. 
2.3. c-IAP1 Knock-Down 
We next used a siRNA-c-IAP1 construct to knock down endogenous c-IAP 1 in a human  
T-Rex-293 stable cell line that overexpressed FLAG-tagged wild-type PCSK9. We observed 
significantly increased pro-PCSK9 species (90% PCSK9 protein is still pro-PCSK9, only 10% is 
converted to the mature species) in comparison to the non-silencing RNA control (over 90% of PCSK9 
is converted to the mature species), indicating that c-IAP1 is directly involved in processing PCSK9 
from the proprotein to the functionally mature protein (Figure 3A). We detected much less secreted 
mature PCSK9 protein in medium collected over 2 days from c-IAP1 siRNA treated versus control 
siRNA treated samples (in 100 mL medium, siRNA treated cells (1 × 107 cells) yielded 20 µg protein, 
whereas the control siRNA treated sample yielded 100 µg protein (1 × 107 cells) (Figure 3A, lower 
panel). We have also detected high-molecular weight aggregates of the pro-PCSK9 protein in c-IAP1 
siRNA cells (Figure 3A). 
We then used c-IAP1 null mouse embryonic fibroblasts (MEFs [11]) to analyse PCSK9 processing. 
As shown in Figure 3B, only 17% pro-PCSK9 is converted to the mature polypeptide in c-IAP1 
knockout MEF cells in comparison to the matched wild-type MEF cells, where over 67% of PCSK9 is 
converted to the mature species. We were unable to detected any secreted PCSK9 in culture 
supernatants in c-IAP1 null MEFs (1 × 107 cells, ref. [11]) collected on the first day (n = 3) and on the 
seventh day (n = 3); while in matched wild-type MEFs cells, there was a steady increase in secreted 
PCSK9 protein in the supernatant (1 × 107 cells) from 1,687 ± 96 pg/mL on the first day (n = 3)  
and 4,320 ± 450 pg/mL on the seventh day, n = 3). There is also a significant increase in the LDLR 
protein level (70% ± 15, Figure 3B) in c-IAP1 knockout MEF cells in comparison to matched  
wild-type MEF cells. 
2.4. Ubiquitination of PCSK9 by c-IAP1 
As c-IAP1 is a well-known E3 ubiquitin ligase, we then tested c-IAP1s ability to ubiquitinate 
PCSK9 in vivo and in vitro. T-Rex-293 cells were co-transfected with wild-type FLAG-tagged PCSK9 
or a gain-of-function mutant construct, PCSK9-D374Y-pcDNA3, and pcDNA3.1-(HA-ubiquitin) 
with or without a CMV-driven c-IAP1 expression vector. After 24 h, whole cell lysates were 
immunoprecipitated with anti-Flag antibody and probed with anti-HA antibody. As shown in Figure 4A, 
both the HA-UB/c-IAP1/PCSK9 wild-type PCSK9 and D374 mutant combination resulted in an 
appearance of multiple high-molecular weight bands representing conjugated HA-Ubiquitinated 
PCSK9 [12] (Figure 4A, lanes 3 and 4). We have identified lysine 27 on the ubiquitin, as a participant 
in the ubiquitination of PCSK9 by the LC/MALDI/MS/MS based approaches [13] (Supplementary 
Figure S3). We have therefore used cells co-transfected with wild-type FLAG-tagged PCSK9  
or a gain-of-function mutant construct, PCSK9-D374Y-pcDNA3, and pRK5-HA-Ubiquitin-K27  
with or without a CMV-driven c-IAP1 expression vector. After 24 h, whole cell lysates were 
immunoprecipitated with anti-Flag antibody and probed with anti-HA antibody. As shown in Figure 4B, 
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both the wild-type PCSK9 and D374 mutant combination resulted in an appearance of multiple  
high-molecular weight bands representing conjugated HA-Ubiquitinated PCSK9 (Figure 4B, lanes 3 
and 4). For the in vitro ubiquitin assay, FLAG-tagged D374Y-PCSK9 and wild-type-PCSK9 were 
purified and subjected to ubiquitination in the presence or absence of recombinant c-IAP1 (Figure 4C). 
PCSK9 was ubiquitinated by c-IAP1, as shown by the appearance of multiple high-molecular weight 
bands on a SDS-PAGE gel representing polyubiquitinated PCSK9 in the presence of recombinant  
c-IAP1 in both PCSK9-D374Y mutation and wild-type PCSK9 respectively(Figure 4C, lanes 2 and 3). 
Figure 3. c-IAP1 Knock-down. (A) A wild-type PCSK9 overexpressed T-Rex-293 stable 
cell line was transfected with pGB c-IAP1 siRNA and a Western blot was probed with 
anti-c-IAP1 or anti-PCSK9 antibodies. Scanning densitometry analysis of three western 
blots is shown below. Data are presented as the percentage conversion to mature PCSK9 
(p63), calculated as the p63 value divided by the sum of p63 + p75 (Pro-PCSK9), divided 
by the tubulin, multiplied by 100. ** indicates a significant difference (p = 0.009) from  
c-IAP siRNA treated cells from control siRNA cells. Lower panel: Coomassie-Blue-stained 
secreted PCSK9 isolated from the 100mL of cultured medium over 2 days from c-IAP1 
siRNA treated or control siRNA treated samples; (B) Western blot analysis of the LDLR 
and PCSK9 protein in c-IAP1-deficient (c-IAP1í/í, reference 11) MEFs and the matched 
wild-type (Wt) MEFs. The percentage conversion to mature PCSK9 level was calculated  
as described above. LDLR amounts were quantified and normalised to the amount of  
D-tubulin in three experiments. The ratio of LDLR/tubulin in c-IAP1 deficient cells was 
assigned a value of 1.00. ** Indicates a significant difference (p < 0.01) between c-IAP1 
deficient MEF cells and matched wild-type MEF cells.  
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Figure 4. Identification of PCSK9 as a substrate of c-IAP1 ubiquitin ligase in vivo and in vitro. 
(A) pcDNA.3-Empty vector or HA-tagged wild-type ubiquitin plasmid were co-transfected 
with FlAG-PCSK9wt or FLAG-PCSK9-D374Y expression vector with or without the 
pCMVc-IAP1 plasmids (Image clone 3908352) into T-REX 293 cells. 24 h later, the 
transfected cells were treated with MG132 (10 PM) for 1 h, the lysates were 
immunoprecipitated using the FLAG-immunoprecipitation kit, the elution samples were 
then analyzed by Western blotting with anti- HA-Tag polyclonal antibody to detect the 
conjugated HA-ubiquitinated PCSK9. Western blots shown are representative of three 
separate experiments; (B) pcDNA.3-Empty vector or pRK5-HA-Ubiquitin-K27 plasmid 
were co-transfected with FlAG-PCSK9wt or FLAG-PCSK9-D374Y expression vector with 
or without the pCMVc-IAP1 plasmids into T-REX 293 cells. The immunoprecipitation 
and the western blots analysis were carried out as in A: again, Western blots shown are 
representative of three separate experiments; (C) FLAG-tagged wild-type-PCSK9 and 
PCSK9-D374Y were subjected to ubiquitination assays in the presence of recombinant c-IAP1. 
The ubiquitinated PCSK9 was detected by immunoblotting with anti-PCSK9 antibody;  
(D) Proposed model of c-IAP1 and PCSK9 interaction. c-IAP1 can bind to PCSK9 and 
promote its maturation. c-IAP1 is also targeting the PCSK9 by K27-linked ubiquitination, 
which lead to the PCSK9/LDLR complex into lysosome, eventually lead to the complex 
degradation.  
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Figure 4. Cont. 
 
2.5. Discussion 
c-IAP1 has two roles in regulating the activities of PCSK9. In its first role, by binding to PCSK9,  
c-IAP1 promotes its maturation from the proprotein form to the mature form. This conclusion is 
supported by compelling evidence. One of the gain-of-function mutations, S127R, is defective with 
respect to binding to c-IAP1, and thus has defective autocatalytic activity. Knockdown of c-IAP1 
impairs PCSK9 processing and autocatalytic cleavage. In c-IAP1 null mouse embryonic fibroblasts 
(MEFs), there is a dramatic decrease in secreted mature PCSK9 protein, while in the wild-type MEF 
cells, proprotein form of the PCSK9 was properly processed and secreted into cell supernatants in a 
reasonable quantity and was functional in mediating degradation of LDLR protein in MEF cells in 
published data [14] and our own results (Supplementary Figure S4). 
The second role of c-IAP1 is its E3 ligase activity in ubiquitinating PCSK9. Both wild-type PCSK9 
and PCSK9-D374Y can be ubiquitinated in the in vivo and in vitro transfection. We found that  
wild-type PCSK9 polyubiquitination mainly involved lysine residue 27 of ubiquitin (Figure 4B).  
K27-linked polyubiquitination was shown to promote lysosomal localization of Jun [15]. It is well 
established the PCSK9 chaperones the LDLR into lysosome. Our results for the first time, highlight 
the possibility of c-IAP1 targeting the PCSK9 by K27-linked ubiquitination, which then lead to the 
PCSK9/LDLR complex into lysosome (Figure 4D). 
PCSK9 is a endoplasmic/vesicular protein [5], while c-IAP1 is known to localize in the 
cytoplasm/nucleus. However, recent research has shown that c-IAP1 is also localized in the 
endoplasmic reticulum and vesicular compartment [16,17]. Wu et al. have found that the c-IAP1 was 
co-localized with ER transmembrane ubiquitin-conjugating enzyme E2 6 (Ubc 6), which served as a 
cognate E2 for c-IAP1s E3 activity [16]. The c-IAP1 has also been co-localized with endoplasmic 
reticulum marker, calreticulin [16]. Calreticulin is a calcium-binding chaperone that is highly 
concentrated in the lumen of the endoplasmic reticulum [18]. In the TWEAK-FN14 signaling  
pathway [17], binding of TWEAK to endogenous FN14 recruits a complex containing both cIAP1 and 
TRAF2 and the complex is recruited to a lysosomal compartment where it is degraded. Consistent with 
lysosomal degradation, TWEAK-induced TRAF2 degradation is prevented by several different 
inhibitors of lysosomal function, such as chloroquine and NH4Cl [17]. Interestingly, PCSK9 mediated 
LDLR degradation also occurred via the lysosomal pathway and can be inhibited by same set of 
lysosomal acidotropic agents such as NH4Cl and chloroquine [19]. Therefore, it is possible that c-IAP1 
could escort the PCSK9/LDLR complexes to the lysosome (Figure 4D). More recently, c-IAP1 has 
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been shown to directly binds to and processes procaspase-3 and procapspase-7 [20]. The fact that  
the endoplasmic reticulum is the main site for caspase-3 activation [21] indicates that c-IAP1 being 
localized in the endoplasmic reticulum and vesicular compartment plays important parts in its diversity 
roles in the TNF-mediated signal transduction pathway. 
However, the precise mechanism by which the S127R mutant proprotein promotes LDLR 
degradation and causes hypercholesterolaemia remains elusive. The S127 resides in the prodomain.  
It is strictly conserved within primate, mouse, and rat PCSK9. From our results, this mutation has 
altered the recognition of the site for c-IAP1 binding and autocatalytic activity, thereby decreasing 
PCSK9 maturation and secretion in this mutant. Although the autocatalytic process of PCSK9 is 
necessary for its maturation and secretion, the catalytic activity is not required for secreted PCSK9 to 
reduce LDLR as a catalytically inactive PCSK9 or a catalytically inert variant of a gain-of-function 
mutant showed no loss of activity in degrading LDLR [22]. Structural studies suggest that residue 127 is 
more than 40 Å from the LDL receptor-binding site [23], and overwhelming biochemical studies have 
shown that the PCSK9-S127R mutant does not have an increased affinity for the LDLR [23,24],  
In contrast to the other gain of function, D374Y, which has significant higher affinity (530 fold) for 
the LDLR than the wild-type protein [23,24]. One possibility is that S127R could bind to other E3 
ligases to regulate the LDLR/PCSK9 intracellular trafficking. In our preliminary shotgun proteomic 
analysis of S127R vs. wild-type PCSK9, an E3 ligase, Stub1 (STIP1homology and U-box containing 
protein 1), also known as CHIP (C terminus of HSC70-Interacting Protein) [25], was found to bind 
much more strongly to S127R than to wild-type PCSK9 (Xu et al., unpublished data, Supplementary 
Figure S5). Stub1 is a ubiquitin ligase/co-chaperone that participates in protein quality control by 
targeting a broad range of chaperone protein substrates, including Hsp70, Hsc70 and Hsp90. 
Interestingly, Stub1 also mediates the formation of K27-linked ubiquitin chains on Bag1, which 
stimulates the ability of Bag1 to bind to the proteasome [26]. It is possible that c-IAP1 and Stub1 E3 
ligases are both involved in the PCSK9 processing for lysosomal or proteasomal pathways. In addition, 
another E3 ligase, Inducible degrader of the LDLR (Idol) has been found to be involved in ubiquitination 
of the LDL receptor [27]. The precise roles of the E3 ligase families in PCSK9-mediated LDLR 
pathway remain to be explored. Further clarification of this pathway will open completely new 
avenues for exploring novel treatments for cardiovascular and infectious diseases. 
3. Experimental  
3.1. Cell Culture and Immunofluorescence Staining and Image Analysis 
HepG2 cells were obtained from the European Cell Culture Collection (Wiltshire, UK). T-Rex 293 
cells were obtained from Invitrogen (Paisley, UK). Cells were grown in DMEM containing  
25 mM glucose and 10% fetal calf serum, as described [28]. c-IAP1 null mouse embryonic fibroblasts 
(MEFs) and matched wild-type MEFs cells were kindly provided by Dr. John Silke and grown in 
DMEM containing 25 mM glucose and 8% fetal calf serum, as described [11]. Fluorescence 
immunohistochemistry was carried out as previously described [29]. 
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3.2. DNA Constructs, Transfections and Western Blot Assays 
C-terminal FLAG-tagged Wild-type PCSK9, S127R-PCSK9 and F216L-PCSK9 were kindly 
provided by Jay D. Horton (University of Texas Southwestern Medical Center, Dallas, TX, USA) [8]. 
D374Y mutation was introduced by oligonucleotide-direct mutagenesis with forward primer  
5'-CATTGGTGCCTCCAGCTACTGCAGCACCTGC-3' and reverse primer 5'-GCAGGTGCTGCA 
GTAGCTGGAGGCACCAATG-3' using QuickChange XL Mutagenesis kit (Stratagene, La Jolla, CA, 
USA). The integrity of the construct was confirmed by DNA sequencing. C-terminal MYC-tagged 
LDLR, cIAP1, TRAF2 in CMV6-based mammalian expression vector were obtained from Origene, 
Inc. PCR was used to generate deletion constructs of MYC-tagged c-IAP1, containing only BIR1 or 
BIR2 or BIR3 domains. The PCR products were cloned in frame to the pCMV6 entry clone (Origene, 
Rockville, MD, USA) with Sgf1 and Mlu1 restriction sites. The successful creation of all constructs 
was confirmed by DNA sequencing. HA-tagged ubiquitin plasmid (plasmid 18712) and pRK5-HA-
Ubiquitin-K27 (plasmid 22902) were purchased from Addgene (Cambridge, MA, USA). CMV-drive 
c-IAP1 expression vector (Image clone 3908352, pCMV-Sport6) was from Geneserve (Cambridge, 
UK). All the transfection were done on T-Rex293 cells or HepG2 cells using superfect (Qiagen, 
Crawley, UK)with 12 ȝg DNA. Cell lysis and western blot analysis were carried out as previous 
described [28]. The antibodies used were a rabbit antibody directed against amino acids 184196 of 
human LDLR (Research Diagnostics Inc. Flanders, NJ, USA) and a rabbit antibody against PCSK9 
(Cayman, Ann Arbor, MI, USA). Anti-mouse/human mature LDLR antibody is from BioVision 
(Milpitas, CA, USA). Other antibodies, including c-IAP1, TRAF2, PDIA4, DNJA1 were from Abcam 
(Cambridge, UK). To detect mouse c-IAP1, a c-IAP1 antibody, mAb (1E1-1-10) (ENZO, Farmindale, 
NY, USA) was used to detect the difference between knock-out mouse c-IAP1 MEF and wild-type 
cells. The antibody was also used to confirm the results from the anti-c-IAP1 antibody from Abcam for 
human c-IAP1 detection and immunohistochemistry. Goat anti-UGGT-1 antibody was from  
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-Stub1 antibody and anti-MYC tag antibody 
9E10 were from Millipore (Billerica, MA, USA). HA-Tag polyclonal antibody was from Clontech 
(Mountain View, CA, USA). All transfections were done with either T-Rex 293 cells and HepG2 cells 
using Superfect (Qiagen). The methods of whole cell extraction and Western blots were carried out as 
described [28].Western blot densitometry was carried out using the Visionworks LS software (UVP, 
Cambridge, UK). All data were analysed by the statistical program GB-Stat V5.4 (Dynamic 
Microsystems, Silver Spring, MD, USA, and SigmaStat, Jandel Scientific, San Rafel, CA, USA). Data 
were presented as means ± SD, and significance of differences among means was estimated by 
Students t-test (two-tailed). p values of <0.05 were considered statistically significant. 
3.3. Generation of Stable Cell Lines, Immunoprecipitation (IP) and Protein Purification 
The PCSK9 expression plasmids were co-transfected with pTK-hygromycin (BD, San Jose, CA, 
USA) into T-Rex 293 cells. 48 h later, cells were subjected to selection with 50 ȝg/mL of hygromycin. 
The positive clones, which over expressed FLAG-tagged PCSK9 were detected by Western blot. 
FLAG-tagged protein IP was carried out by using FLAG-tagged protein immunoprecipitation kit 
(FlagIPT-1, Sigma, Dorset, UK) with final elution using 3xFLAG peptide (final concentration  
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150 ng/ȝL of 3xFLAG peptide). MYC tagged protein was immunoprecipitated with Pierce 
Mammalian c-Myc Tag IP/Co-IP kit (Waltham, MA, USA). PCSK9 proteins from the tissue culture 
mediums of the stable expressed 293 cell lines, including wild-type, D374Y and S127R PCSK9 were 
purified using FLAG-M Purification Kit (Sigma, Dorset, UK) following the manufacturers 
instruction. The final elution was concentrated with vivaspin 6 (Artoris Stedim Biotech, Surrey, UK) 
and dialysed against PBS using a Slid-A-lyzer mini dialysis unit (Thermo Scientific). Protein 
concentration was measured using Bio-Rad Protein Assay kit, Cat:500-0006, Bio-Rad. Hemel 
Hempstead, UK). The protein purity was determined by SDS-PAGE and visualized by Coomassie 
Blue stain with over 90% purity. 
3.4. Shotgun Analysis of the FLAG-Tagged PCSK9 and Associated Proteins Complex Samples 
A stable expressed FLAG-tagged PCSK9 cell line was grown in DMEM medium with 10% FBS. 
The FLAG-tagged PCSK9 protein was isolated using the FLAG-immunoprecipitation kit (Sigma, 
Dorset, UK) following by elution with the 3xFLAG peptide (final concentration 150 ng/ȝL of 
3xFLAG peptide). The elution samples were then sent to the Protein Analysis Facility, Center  
for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, 
Switzerland, where protein mixtures were separated by limited electrophoresis after which 35 molecular 
weight regions were cut and digested. Analysis was performed by LC-MS/MS on every fraction. The 
resulting spectra were pooled for every sample before a database search. The lists of identified proteins 
for each sample with their scores were subjected to statistical validation and aligned for comparison 
with Scaffold program. A negative control cell line, T-Rex-293 cells transfected with the empty vector 
pcDNA3.1 was used for background subtraction. 
3.5. RNA Interference 
c-IAP1 siRNA mix (pGB-cIAP1 siRNA, Biovision Research Products, Milpitas, CA, USA) or 
control siRNA (pGB-control) were transfected into a stable wild-type PCSK9 overexpression cell line 
using the superfect reagent (Qiagene, Crawley, UK). After 48 h, the cells were subjected G148 
selection to obtain the stable cell lines with nearly 100% knock-out the c-IAP1 protein as determined by 
Western blot analysis. 
3.6. Mouse PCSK9 Immunoassay 
The cell culture supernatants (from 1 × 107 cells in T75 flasks) from c-IAP1 null mouse embryonic 
fibroblasts (MEFs) and matched wild-type MEFs cells [11] were collected. The mouse PCSK9 
immunoassay kit (Cat MPC900, R&D system, Minneapolis, MN, USA) was used to quantitatively 
determine the PCSK9 concentration in cell culture supernatants according to the manufacturers 
recommended protocol. To ensure equal numbers of cells were used, the protein concentration of cell 
lysis was measured using the Bio-Rad protein assay kit (Bio-Rad, Hemel Hempstead, UK). 
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3.7. In Vivo Ubiquitination Analysis 
pcDNA.3-Empty vector or HA-tagged ubiquitin plasmid (kindly provided by Edward Yeh [12])  
and pRK5-HA-Ubiquitin-K27 (kindly provided by Sandra Weller [30]) were co-transfected with 
FlAG-PCSK9wt or FLAG-PCSK9-D374Y expression vector with or without the pcDNA6c-IAP1 
plasmids into T-REX 293 cells. 24 h later, the transfected cells were treated with MG132 (10 ȝM) for 
1 h before the lysates were immunoprecipitated using the FLAG-immunoprecipitation kit (Sigma), the 
elution samples were then analyzed by Western blotting with anti- HA-Tag polyclonal antibody 
(Clontech, Mountain View, CA, USA). 
3.8. In Vitro Ubiquitination Assay 
Purified FLAG-tagged wild-type PCSK9 (4 ȝg) and D374Y-PCSK9 (1 ȝg) and recombinant  
c-IAP1 (1 ȝg, R&D System) were incubated in a reaction buffer (50 mM Tris-HCl (pH 7.5), 5 mM 
MgCl2, 2 mM ATP, 0.6 mM DTT) with recombinant rabbit E1 (100 ng), UbcH5b (250 ng) and 
ubiquitin (6 ng) at 37 °C for 2 h. The resulting mixtures were analyzed by immunoblotting using  
anti-PCSK9 antibody. 
3.9. Mass Spectrometric Analysis of Ploy-Ubiquitinated PCSK9  
Five ȝg of PCSK9-wild type protein was ubiquitinated in vitro as above. The poly-ubiquitinated 
PCSK9 bands were cut in small pieces and washed 2× with 100 ȝL of 100 mM NH4HCO3/50% 
acetonitrile, washed 1× with 50 ȝL acetonitrile. Gel slices then were digested with trypsin overnight. 
Samples were dissolved in 15 ȝL 0.1% TFA. 2 × 4 ȝL of each sample were added on the HPLC 
column and the spotted on a plate. The plates were analyzed in an automatic warp-run. The 
LC/MALDI/MS/MS measurements were performed automatically. Database searches were performed 
by using the Mascot (NCBI: all species) search program including check for possible contact lysine 
residue to the ubiquitin. This is the remaining molecule part of the ubiquitin part after trypsinisation 
(GG) (LRGG) [13]. 
4. Conclusions  
c-IAP1 has two roles in regulating PCSK9 activities. The first role is that by binding to PCSK9, it 
promotes its maturation from the proprotein form to the mature form. The second role of c-IAP1 is its 
E3 ligase activity in ubiquitinating PCSK9. The finding indicates the c-IAP1 acts on both secretion of 
PCSK9 and its lysosomal localization. 
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